| Project/Area Number |
17590231
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Nigata University of Phermacy and Applied Life Sciences |
|---|
Principal Investigator |
NAGATOMO Takafumi Nigata University of Phermacy and Applied Life Sciences, Faculty of Pharmaceutical Science, Dept. of Pharmacology, Professor (60121240)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ONUKI Toshio Niigata University of Pharmacy and Applied Life Scienses, Faculty of Pharmaceutical Science Dept. of Pharmacology, Assistant (60288230)
SUGIHARA Takumichi Niigata University of Pharmacy and Applied Life Scienses, Faculty of Pharmaceutical Science Dept. of Organic and Medicinal Chemistry, Professor (40222054)
金子 喜三好 新潟薬科大学, 薬学部, 教授 (90133462)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥330,000)
Fiscal Year 2007: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2006: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 2005: ¥1,500,000 (Direct Cost: ¥1,500,000)
|
|---|
| Keywords | 5-HT2A receptors / sarpogrelate / modeling / structure-activity relationships / inverse agonist / constitutively active / インバースアゴニスト / 5-HT_<2A>遮断薬 / NMR / 5-HZ_2遮断薬 / 5-HT_<2A>結合部位 |
|---|
| Research Abstract |
Mutations producing constitutively active G-protein coupled receptors (GPCRs) have been found in the pathophysiology of several diseases, implying that inverse agonists at the constitutively active receptors may have preferred therapeutic applications. Because of the involvement of 5-HT_<2A> receptors in mediating many cardiovascular diseases, constitutively active mutants of the 5-HT_<2A> receptor may be responsible for the disease states. Thus, the purpose of the present study was to investigate the inverse agonist activity of sarpogrelate, a selective 5-HT_<2A>-receptor antagonist, and its active metabolite, M-1; and we compared their activities with those of other 5-HT_<2A>-receptor antagonists such as ritanserin, ketanserin, and cyproheptadine. Using a constitutively active mutant (C322K) of the human 5-HT_<2A> receptor, we demonstrated that like other 5-HT_<2A>-receptor antagonists, sarpogrelate acts as a potent inverse agonist by significantly reducing basal inositol phosphate (IP) levels. However, there were no significant differences between sarpogrelate and other 5-HT_<2A>-receptor antagonists for their inverse agonist activity. Compared with the wild type receptor, mutant receptor displayed significantly higher affinity for 5-HT and lower affinity for sarpogrelate. These results indicate that stabilization of the inactive conformation of the 5-HT_<2A> receptor may be a key component of the mechanism of action of sarpogrelate.
|
